Eliminating the need for sequential confirmation of response in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Multiple myeloma progression assessment relies on serial measurements of monoclonal proteins.
• Current International Myeloma Working Group criteria require two sequential assessments for confirmation, which can be time-consuming in clinical trials.

Purpose of the Study:

• To evaluate if simultaneous progression criteria for two disease markers can obviate the need for sequential testing.
• To determine if a single assessment of two markers meeting progression criteria is sufficient for confirming disease progression in multiple myeloma.

Main Methods:

• Retrospective analysis of sequential multiple myeloma patients enrolled in clinical trials at Mayo Clinic.
• Identification and analysis of confirmed progression episodes based on established criteria.
• Evaluation of sensitivity and specificity of simultaneous versus sequential marker assessment for progression.

Main Results:

• Nearly 70% of 583 confirmed progression episodes met the simultaneous two-marker criteria upon initial testing.
• Among 413 patients meeting progression by two simultaneous values, 98% subsequently confirmed progression via sequential testing.
• This suggests high sensitivity and specificity for the simultaneous assessment approach.

Conclusions:

• Simultaneous assessment of two disease burden markers meeting progression criteria may eliminate the need for sequential testing.
• This streamlined approach could improve efficiency in clinical trial assessments for multiple myeloma.
• Further validation may support revising current progression assessment guidelines.